Prior Opioid Exposure Influences Parents’ Sharing of Their Children’s
            <i>CYP2D6</i>
            Research Results

Myers, Melanie F.; Zhang, Xue; McLaughlin, Brooke M.; Kissell, Diane; Perry, Cassandra; Veerkamp, Matthew; Zhang, Kejian; Holm, Ingrid A.; Prows, Cynthia A.

doi:10.2217/pgs-2017-0091

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous case/control study found that parents of children exposed to opioids were more likely to share the child’s CYP2D6 results with their primary care provider as compared to children not exposed to opioids, and believed their child’s doctor could use that information for improved care. 19 Additionally, the disease state that is being treated may influence the likelihood or the extent to which parents or individuals pursue PGx testing. Diagnoses such as attention deficit hyperactivity disorder, which can be challenging for the parent, patient, and provider, have PGx panels specifically marketed by companies for this disease state.…”

Section: Relationship Between the Medxp And Pgxmentioning

confidence: 99%

How Pharmacogenomics Informs and Influences the Medication Experience

Olson,

Brown

2024

Innov Pharm

View full text Add to dashboard Cite

Both pharmacogenomics (PGx) and the medication experience (MedXp) share a common purpose for their use, which is to optimally tailor pharmacotherapeutics to each unique individual. The former pursues this aim by using an individual’s genetic makeup, while the latter considers the subjective experience of medication-taking in one’s life. The different ways by which these fields of study pursue their shared aim have resulted in relatively little understanding of their relationship when utilized in care processes to produce health outcomes. This commentary explores this gap and identifies implications for future research that can help close it to improve person-centered care.

show abstract

Section: Relationship Between the Medxp And Pgxmentioning

confidence: 99%

How Pharmacogenomics Informs and Influences the Medication Experience

Olson,

Brown

2024

Innov Pharm

View full text Add to dashboard Cite

show abstract

Implementation of CYP2D6-guided opioid therapy at Cincinnati Children’s Hospital Medical Center

Ramsey

Prows

Chidambaran

et al. 2023

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose We describe the implementation of CYP2D6-focused pharmacogenetic testing to guide opioid prescribing in a quaternary care, nonprofit pediatric academic medical center. Summary Children are often prescribed oral opioids after surgeries, for cancer pain, and occasionally for chronic pain. In 2004, Cincinnati Children’s Hospital Medical Center implemented pharmacogenetic testing for CYP2D6 metabolism phenotype to inform codeine prescribing. The test and reports were updated to align with changes over time in the testing platform, the interpretation of genotype to phenotype, the electronic health record, and Food and Drug Administration guidance. The use of the test increased when a research project required testing and decreased as prescribing of oxycodone increased due to FDA warnings about codeine. Education about opioid-focused pharmacogenetic test was provided to prescribers (eg, the pain and sickle cell teams) as well as patients and families. Education and electronic health record capability increased provider compliance with genotype-guided postsurgical prescribing of oxycodone, although there was a perceived lack of utility for oxycodone prescribing. Conclusion The implementation of pharmacogenetic testing to inform opioid prescribing for children has evolved with accumulating evidence and guidelines, requiring changes in reporting of results and recommendations.

show abstract

Building a Population Representative Pediatric Biobank: Lessons Learned From the Greater Cincinnati Childhood Cohort

Martin

Murrison

Kovacic

2021

Front. Public Health

View full text Add to dashboard Cite

Background: Biobanks can accelerate research by providing researchers with samples and data. However, hospital-based recruitment as a source for controls may create bias as who comes to the hospital may be different from the broader population.Methods: In an effort to broadly improve the quality of research studies and reduce costs and challenges associated with recruitment and sample collection, a group of diverse researchers at Cincinnati Children's Hospital Medical Center led an institution-supported initiative to create a population representative pediatric “Greater Cincinnati Childhood Cohort (GCC).” Participants completed a detailed survey, underwent a brief physician-led physical exam, and provided blood, urine, and hair samples. DNA underwent high-throughput genotyping.Results: In total, 1,020 children ages 3–18 years living in the 7 county Greater Cincinnati Metropolitan region were recruited. Racial composition of the cohort was 84% non-Hispanic white, 15% non-Hispanic black, and 2% other race or Hispanic. Participants exhibited marked demographic and disease burden differences by race. Overall, the cohort was broadly used resulting in publications, grants and patents; yet, it did not meet the needs of all potential researchers.Conclusions: Learning from both the strengths and weaknesses, we propose leveraging a community-based participatory research framework for future broad use biobanking efforts.

show abstract

Prior Opioid Exposure Influences Parents’ Sharing of Their Children’s CYP2D6 Research Results

Abstract: Prior opioid exposure influenced perceived clinical utility and sharing behaviors.

Cited by 3 publications

References 49 publications

How Pharmacogenomics Informs and Influences the Medication Experience

How Pharmacogenomics Informs and Influences the Medication Experience

Implementation of CYP2D6-guided opioid therapy at Cincinnati Children’s Hospital Medical Center

Building a Population Representative Pediatric Biobank: Lessons Learned From the Greater Cincinnati Childhood Cohort

Contact Info

Product

Resources

About